The WHO defines AML more appropriately than ICC for the entities AML with PML::RARA rearrangement, with NPM1 mutation, with KMT2A rearrangement, and with MECOM rearrangement. This evidence concerns the gene RARA and intrahepatic cholangiocarcinoma.